Comprehensive Analysis to Identify Rh Family C Glycoprotein (RHCG) as the Causative Gene for Psoriasis and Search for Alternative Treatment Modalities
Qian Zhang,Jia Liu,Dan Yao,Jian-Xin Shi,Yuan-Jie Liu,Yue-Gang Wei,Shun Guo
DOI: https://doi.org/10.2147/dddt.s421300
2023-08-28
Abstract:Qian Zhang, 1, 2, &ast Jia Liu, 1, &ast Dan Yao, 1, 2 Jian-Xin Shi, 1 Yuan-Jie Liu, 2– 4 Yue-Gang Wei, 1 Shun Guo 1, 2 1 Department of Dermatology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu, 210029, People's Republic of China; 2 No. 1 Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, People's Republic of China; 3 Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu, 210029, People's Republic of China; 4 Key Laboratory of Tumor System Biology of Traditional Chinese Medicine, Nanjing, Jiangsu, 210029, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shun Guo, Email Background: Psoriasis is a complex autoimmune disease. Frequent interactions between epidermal and immune cells are likely to be responsible for the strong heterogeneity of psoriasis. Therefore, our work aims to build on current knowledge and further search for new molecular mechanisms related to psoriasis pathogenesis in order to develop new targeted drugs. Methods: Data from psoriasis samples were obtained from the Gene Expression Omnibus (GEO) database, and batch effects were corrected using the "Combat" algorithm in the "SVA" package. Functional annotation of differential genes in psoriasis was performed by Gene set enrichment analysis (GSEA). Core functional modules were identified using the Multiscale Embedded Gene Co-Expression Network Analysis (MEGENA) algorithm for selection from the differential gene interaction network. The expression and potential function of Rh Family C Glycoprotein ( RHCG ) was predicted in single cell data by the "Seurat" package and validated in psoriasis samples by multiplex immunofluorescence. In addition, the regulatory function of HOP Homeobox ( HOPX) on RHCG in keratinocytes was confirmed using RNA interference. Using immune infiltration analysis, RHCG and DC cells were analyzed for their association. Finally, the molecular mechanisms of treatment of psoriasis using Tripterygii Radix (TR) and Cinnamomi Ramulus (CR) were explored through network pharmacology and experimental validation. Results: Immune response (represented by C1_2) and collagen matrix formation (represented by C1_3) were identified as two important pathogenic factors in psoriasis and helped to define new biological subtypes of psoriasis. One important psoriasis hub gene, RHCG , was obtained and found to be closely associated with keratinocyte differentiation as well as DC cell maturation. And RHCG was regulated by HOPX in keratinocytes. In addition, the mechanism of action of CR and TR in the treatment of psoriasis was tentatively confirmed to be related to TRPV3, NFKB2, and YAP1. Conclusions: Our study identifies a new causal disease gene (RHCG) and offers potential alternatives for the treatment of psoriasis. Keywords: psoriasis, Rh family C glycoprotein, RHCG , DC cells, keratinocyte, traditional Chinese medicine Psoriasis, a chronic recurrent skin disease triggered by environmental factors, has an incidence of about two percent. 1 The underlying pathogenesis of psoriasis stems from a complex interplay among immune cells, skin cells and many cytokines. 2 The prevailing view is that abnormal expression of cytokines, including tumor necrosis factor (TNF) and interleukins (IL), leads to over-proliferation of keratinocytes and dysfunction of the immune system, which ultimately induces the visible skin phenotype. 3 In recent years, various biologics targeting cytokines have gradually become the mainstay of treatment for moderate to severe psoriasis because of their ability to significantly alleviate clinical symptoms and improve patients' quality of life. 4,5 These include etanercept, adalimumab, certolizumab, and infliximab, which inhibit the action of tumor necrosis factor-1 (TNF-1). There are a number of other biologics inhibit cytokines, including those that inhibit the p40 subunits of IL-12 and IL-13 (ustekinumab), the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab, and mirikizumab), and IL-17 (secukinumab, ixekizumab, bimekizumab, and brodalumab). However, not all patients benefit from biologic therapies, and most have to endure frequent adverse events and relapses. 6 The autoimmune cascade of psoriasis poses a great challenge to the treatment of psoriasis due to the wide range of biological effects involved. -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal